Biocon Rises After Subsidiary Gets USFDA Tentative Nod for Rifaximin Tablets 550 mg
Mumbai, October 7 (Udaipur Kiran): Shares of Biocon edged higher after its wholly owned subsidiary Biocon Pharma, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg. The stock is currently trading at ₹348.95, up ₹1.70 … Read more
